Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Codes

ICD-10 Codes:

XW033C3 - Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3

XW043C3 - Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3

ICD-10 Diagnosis Codes:

C91.00 - Acute lymphoblastic leukemia not having achieved remission
C91.02 - Acute lymphoblastic leukemia, in relapse
C82.0-C82.99 - Follicular lymphoma
C83.30-C83.39 - Diffuse large B-cell lymphoma
C85.20-C85.29 - Mediastinal (thymic) large B-cell lymphoma
Z51.11 - Encounter for antineoplastic chemotherapy
Z51.12 - Encounter for antineoplastic immunotherapy

Drug Codes:

Q2042 - Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Kymriah) – new code effective 1-1-19

Q2041 - Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Yescarta)

Hospital Billing:

REV 87x = 087x Cell/Gene Therapy - Charges for procedures performed by staff for the acquisition and infusion/injection of genetically modified cells.

REV 89x = 089x Pharmacy - Extension of 025x and 063x - 0891 Special Processed Drugs - FDA Approved Cell Therapy(a) DRUGS/CELL THERAPY

Procedure Codes for claims submitted on or after April 1, 2019:

HCPCS 0537T with revenue code 0871 - Collection/handling
HCPCS 0538T with revenue code 0872 - Preparation for transport
HCPCS 0539T with revenue code 0873 - Receipt and preparation